Instructions Potassium chloride concentrate for infusion solution 7.5% glass bottle 20 ml
Composition
active ingredient: potassium chloride;
1 ml of solution contains 75 mg of potassium chloride;
excipient: water for injections.
Dosage form
Concentrate for solution for infusion.
Main physicochemical properties: clear colorless liquid;
ionic composition: potassium ion – 1.01 mmol/ml; chloride ion – 1.01 mmol/ml.
Pharmacotherapeutic group
Electrolyte solutions. Potassium chloride.
ATX code B05X A01.
Pharmacological properties
Pharmacodynamics
A remedy that restores potassium deficiency. Helps maintain proper intracellular and extracellular levels of potassium, which is the main intracellular ion that plays an important role in cellular metabolism and the regulation of various body functions. Potassium ions activate a large number of cytoplasmic enzymes, regulate intracellular osmotic pressure, increase the tone of the sympathetic division of the autonomic nervous system, increase the production of adrenaline by the adrenal glands, stimulate the synthesis of ATP, glycogen, proteins, acetylcholine. Reduce heart rate, reduce contractile activity, conductivity, automatism and excitability of the myocardium. In low doses, potassium dilates the coronary vessels, in high doses it constricts them. The drug eliminates electrolyte imbalance in the body, improves metabolism in the myocardium and its energy supply, has antiarrhythmic properties. Reduces increased sensitivity to cardiac glycosides and reduces their cardiotoxic effects.
Pharmacokinetics
When administered by infusion, the drug enters the cells, particularly cardiomyocytes, from the blood in the form of potassium ions. Potassium is involved in cellular metabolism. It is excreted in the urine.
Indication
Tachycardia, extrasystolic arrhythmia caused by hypokalemia, including cardiac glycoside intoxication. Severe hypokalemia (serum potassium concentration less than
2.5 mmol/l).
Contraindication
Acute and chronic renal failure, complete heart block, atrioventricular conduction disorders, hyperkalemia, hyperchloremia, metabolic disorders (hypovolemia with hyponatremia), hyperhydration, systemic acidosis, diabetic acidosis, acute dehydration, significant burns, intestinal obstruction, cerebral edema, Addison's disease. The drug should not be administered simultaneously with blood products.
Interaction with other medicinal products and other types of interactions
The drug improves the tolerance of cardiac glycosides, which allows, if necessary, simultaneous administration of strophanthin or digitalis preparations. Potassium-sparing diuretics, ACE inhibitors, trimethoprim increase the risk of developing hyperkalemia, which requires monitoring of the level of potassium in the blood when used simultaneously with potassium chloride concentrate.
The simultaneous use of potassium chloride with nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of developing hyperkalemia (it is necessary to monitor the level of potassium in the blood serum). Under the influence of potassium preparations, the effect of quinidine on the heart is enhanced, as well as the undesirable effect of disopyramide on the cardiovascular system.
Application features
Use with caution in cases of impaired AV conduction. It should be borne in mind that the toxicity of potassium salts increases in cases of adrenal insufficiency. The drug should be used with caution in patients with intracranial and intraspinal hemorrhages.
Magnesium deficiency, which may accompany potassium deficiency, should also be treated.
In patients with chronic kidney disease or other diseases accompanied by impaired excretion of potassium from the body, or with very rapid intravenous administration of Potassium Chloride 75 mg/ml, hyperkalemia may develop, which can potentially be fatal.
During treatment, it is recommended to regularly monitor the level of potassium in the blood serum, as well as the acid-base balance of the blood, and to conduct periodic ECG monitoring, especially for patients with diseases of the cardiovascular system and kidneys.
Use with caution in diseases of the cardiovascular system, with simultaneous use of potassium-sparing diuretics.
Concomitant parenteral administration of calcium ions may cause arrhythmia.
Abrupt withdrawal of Potassium Chloride when used simultaneously with cardiac glycosides requires special caution, since the hypokalemia that develops in this case increases the toxicity of digitalis.
The contents of the vial can only be used by one patient, any unused portion should be discarded.
Use during pregnancy or breastfeeding
There is no data on contraindications during pregnancy or breastfeeding, but it should be remembered that potassium preparations reduce uterine tone. Use with caution and if there are vital indications in the presence of nephropathy in pregnant women.
Ability to influence reaction speed when driving or using other mechanisms
Since the drug is intended for use in a hospital setting, there is no data on such effects.
Method of administration and doses
The dosage regimen and duration of use are set by the doctor individually under the control of the results of electrocardiography and the level of potassium in the blood serum. As a rule, adults should be prescribed from 0.5 to 2 g of potassium chloride per day. As a solvent, you can use 200-250 ml of 0.9% sodium chloride solution or 5% glucose. The rate of administration is 20-30 drops per minute.
Children
There are no data on the use of the drug in children.
Overdose
It remains asymptomatic for a long time until the concentration of potassium in the blood serum reaches a high level (6.5-8 mmol/l). It is manifested by increased manifestations of adverse reactions. Hyperkalemia and hyperhydration are possible. In this case, patients experience muscle weakness, abdominal pain, paresthesias, frequent shallow breathing, arrhythmia, possible loss of consciousness, increased body temperature, apathy, decreased blood pressure and body weight, mental disorders.
The electrocardiogram shows an increase in the amplitude of the T wave, depression of the ST segment, and expansion of the QRS complex.
In case of overdose, prescribe symptomatic treatment aimed at supporting vital functions. Administer parenterally regular insulin and calcium preparations. If necessary, perform hemodialysis.
Adverse reactions
Electrolyte imbalance:
– hypophosphatemia;
– hypomagnesemia;
– hyperkalemia;
– hyponatremia.
From the digestive tract:
– dyspeptic disorders (nausea, abdominal pain).
From the cardiovascular system:
– bradycardia;
– cardiac conduction disorders, arrhythmia, extrasystole;
– arterial hypotension.
On the part of the immune system:
– allergic reactions (hyperthermia, skin rashes, angioedema, shock).
On the part of the nervous system: in rare cases, when using high doses, weakness, paresthesia, and confusion may occur.
General reactions of the body:
– hypervolemia;
– yadukha;
– sore throat.
Changes at the injection site, including pain, redness, phlebitis.
In case of adverse reactions, the solution should be discontinued. Therapy is symptomatic.
Expiration date
2 years.
Storage conditions
Store at a temperature not exceeding 25 ° C. Do not freeze. Keep out of the reach of children.
Incompatibility
Do not mix with other medicines. Do not use other medicines as a solvent, except those specified in the section "Method of administration and dosage".
Packaging
10 ml or 20 ml in vials; 10 ml or 20 ml in containers.
Vacation category
According to the recipe.
Producer
LLC "Yuria-Pharm".
Location of the manufacturer and its business address
Ukraine, 18030, Cherkasy, Verbovetskogo St., 108.
Tel. (044) 281-01-01.
